Stocktoria

Warby Parker Inc. WRBY

NYSE · XNYS · stock · Ophthalmic Goods
Chart by TradingView
5/9
Piotroski F — financial health
-0.22
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$871.9M$1.6M$470.6M$43.7M$367.7M
2024$771.3M-$20.4M$426.8M$34.7M$340.1M
2023$669.8M-$63.2M$365.2M$7.3M$301.8M
2022$598.1M-$110.4M$341.1M-$49.8M$286.6M
2021$540.8M-$144.3M$317.7M-$80.5M$286.0M
2020$393.7M-$55.9M$231.9M$12.7M-$198.1M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Briggs Teresadirector2026-06-16Sell3,092$25.41
Briggs Teresadirector2026-06-16Sell1,908$26.79
Moon Youngme Edirector2026-06-12Sell10,000$26.53
WILLIAMS RONALD Adirector2026-06-08Grant13,006
SINGER BRADLEY Edirector2026-06-08Grant9,004
Raider Jeffrey Jacobdirector2026-06-08Grant9,004
Hunt Andrewdirector2026-06-08Grant12,005
Moon Youngme Edirector2026-06-08Grant9,004

Why these scores methodology →

Piotroski F-score: 5/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -0.22 (distress)

  • Working capital / assets 0.281
  • Retained earnings / assets -0.951
  • EBIT / assets -0.007
  • Equity / liabilities 1.041

Source: SEC EDGAR filings · CIK 0001504776 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.